DiaMedica Therapeutics Inc

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DiaMedica Therapeutics addresses FDA concerns amidst financial stability

DiaMedica Therapeutics maintains a strong financial position, but faces challenges with the clinical hold on their pivotal trial, requiring proactive resolution.
Despite increased expenses, the company's commitment to addressing regulatory feedback and ensuring patient safety presents growth opportunities in the long term.
Resolving the clinical hold swiftly and resuming trial enrollment are key priorities for DiaMedica to advance their clinical programs and unlock future potential.

DiaMedica progresses on FDA concerns with stable finances and new leadership

DiaMedica Therapeutics is actively addressing FDA concerns on DM199, supported by a stable financial position and a strengthened management team.
While facing challenges in meeting regulatory requirements and managing increased expenses, DiaMedica sees opportunities in resolving adverse events and advancing DM199.
Overall, DiaMedica's progress, financial stability, and strategic additions position the company well for potential FDA approval and further development of DM199.

DiaMedica Therapeutics reports strong Q2 performance and eyes global expansion

DiaMedica Therapeutics made significant progress in Q2 2023, achieving key milestones, strengthening financial position, and advancing product development.
While facing challenges in patient enrollment and legal matters, the company is well-positioned to capitalize on opportunities for global expansion and market growth.
Overall, DiaMedica's focus on efficient treatment delivery and commitment to innovation position them for future success in the biopharmaceutical industry.

DiaMedica reports solid Q3 results amidst strategic protocol enhancements

DiaMedica Therapeutics showcased robust financials in Q3 2023, driven by successful private placements and strategic cost management.
The appointment of Dr. Ambar Shah and protocol enhancements for ReMEDy2 reflect a commitment to innovation and clinical advancement.
However, challenges persist with patient enrollment, protocol adjustments, and legal proceedings, necessitating focused efforts to mitigate risks and drive progress.

DiaMedica Therapeutics reports robust 2023 performance and advances stroke treatment

DiaMedica Therapeutics' strong financial performance and progress in the ReMEDy2 trial highlight the company's growth potential.
Appointment of a new Chief Medical Officer and protocol revisions demonstrate a commitment to advancing clinical development efforts.
While facing challenges in site commitments and trial complexities, the company has opportunities for global expansion and market penetration.

DiaMedica reports robust Q1 earnings, eyes trial expansion opportunities

DiaMedica Therapeutics showcased strong financial performance and positive trial progress in Q1 2024.
While facing challenges such as increased operating expenses and a legal appeal, the company remains well-positioned for growth.
Opportunities lie in expanding trials, leveraging the success in China, and building a robust foundation for future drug development.

DiaMedica Therapeutics progresses on key programs amidst financial stability

DiaMedica Therapeutics is on track for a transformative 2025 with progress on key programs and enrollment enhancements.
Strategic protocol updates and financial stability bolster the company's position for future growth and clinical success.
Challenges around protocol changes and enrollment optimization require careful navigation for sustained progress.
Opportunities lie in protocol enhancements, regulatory milestones, and financial strength to drive innovation and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the year ended December 31, 2022. Management will host a conference call Wednesday, March 29, 2023, at 7:00AM Central Daylight Time/8:00AM Eastern Daylight Time to discuss its business update and full year 2022 financial results.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday, March 28th. DiaMedica will host a live conference call on Wednesday, March 29th at 7:00 AM Central Time to provide a business update and discuss financial results.

DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will present a corporate overview at the virtual Oppenheimer 33rd Annual Healthcare Conference, which will take place March 13th – 15th, 2023. Mr. Pauls is scheduled to present at 2:40 p.m. Eastern Time on Wednesday, March 15, 2023.

DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs. Ms.

DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended September 30, 2022.

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating in the 13th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 17, 2022.

DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022

DiaMedica Therapeutics, Inc. (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO, will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference, which will take place November 8 – 10, 2022 in Rancho Palos Verdes, California.

DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company has received further guidance from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on its ReMEDy2 Phase 2/3 trial for the treatment of acute ischemic stroke (AIS).

DiaMedica Therapeutics Provides Update on ReMEDy2 Trial

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Julie VanOrsdel Daves, MSHS, CCRP, as Senior Vice President (SVP), Clinical Development Operations. Ms. Daves, a recognized leader in managing global clinical studies, has significant experience in all phases of clinical development and will complement DiaMedi

DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market's 6th Annual Best Ideas Growth (BIG6) Conference in New York, on September 14, 2022. Management will conduct one-on-one meetings with investors during the conference. To receive additional

DiaMedica Therapeutics to Present at Lake Street's 6th Annual Best Ideas Growth Conference

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Medical Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alex Nowak - Craig-Hallum Capital Group Elemer Piros - ROTH Capital Partners Francois Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2022 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended June 30, 2022. DiaMedica will host a conference call on Thursday, August 11, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and second quarter financial results. Clinical De

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2022 financial results will be released after the markets close on Wednesday, August 10th. DiaMedica will host a live conference call on Thursday, August 11th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference C

DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company's management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conference, which is taking place both virtually and at the St. Regis New York Hotel in New York City, August 8-9, 2022. For those interested in meeting with DiaMed

DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022

The FDA placed a clinical hold on DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Phase 2/3 ReMEDy2 trial evaluating DM199 to treat acute ischemic stroke patients.  The clinical hold was initiated following the company's pause in patient enrollment and submission.

FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Company's Phase 2/3 ReMEDy2 trial studying the use of the Company's product candidate, DM199, to treat acute ischemic stroke (AIS) patients. The clinical hold was initiated following the Company's

DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 19th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, June 1, 2022. Management will be available to participate in one-on-one meetings. Investors and attendees that would like to schedule a meeting with

DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Capital Group Francois Brisebois - Oppenheimer & Co. Inc. Elemer Piros - ROTH Capital Partners Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2022 Conference Call. An audio recording of the webcast would be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call Transcript

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended March 31, 2022. DiaMedica will host a conference call on Thursday, May 5, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and first quarter financial results. Clinical Develo

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2022 financial results will be released after the markets close on Wednesday, May 4th. DiaMedica will host a live conference call on Thursday, May 5th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call detai

DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2021 Results - Earnings Call Transcript

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the year ended December 31, 2021. Management will host a conference call Tuesday, March 15, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and full year financial results. “Our clinical, regu

DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its fourth quarter 2021 financial results will be released after the markets close on Monday, March 14th. DiaMedica will host a live conference call on Tuesday, March 15th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call de

DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Dominic Cundari as Chief Commercial Officer. In this role, Mr. Cundari will be focused primarily on the commercial planning, positioning and launch preparations for DM199 in acute ischemic stroke. “Dom has extensive experience in successfully launching special

News for DiaMedica Therapeutics Inc Stock (DMAC)